title: [Clarithromycin therapy of a B cell MALT lymphoma].
abstract: Presentation of a 34-year-old patient with a conjunctival tumor of the left upper circumference of the eyeball clinically presenting as a salmon-pink colored conjunctival tumor. The incisional biopsy and immunohistochemical work-up revealed an extranodal conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma of the marginal zone B cell type. The therapy comprised a currently experimental therapy scheme with 500 mg clarithromycin 3 times per day for 21 days. This therapy achieved a significant tumor regression.
authors.affiliation: Augenabteilung, Krankenhauses der Barmherzigen Brüder, Seilerstätte 2, 4020 Linz, Österreich. lukas.danilko@gmx.at
authors.forename: L
authors.initials: L
authors.lastname: Danilko
authors.forename: K
authors.initials: K
authors.lastname: Haas
authors.forename: U
authors.initials: U
authors.lastname: Schönherr
authors.forename: G
authors.initials: G
authors.lastname: Tschurtschenthaler
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage*; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000473:pathology*; D010865:Pilot Projects; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011500:Protein Synthesis Inhibitors; D017291:Clarithromycin